Prevnar family — Competitive Intelligence Brief

Prevnar family (prevnar-family) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

marketed Vaccine Streptococcus pneumoniae Immunology Vaccine

Target snapshot

Prevnar family (prevnar-family) — Pfizer Inc.. Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prevnar family TARGET	prevnar-family	Pfizer Inc.	marketed	Vaccine	Streptococcus pneumoniae
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
GSK1024850A (SynflorixTM)	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
15-valent pneumococcal conjugate vaccine (PCV15)	15-valent-pneumococcal-conjugate-vaccine-pcv15	Pfizer	marketed	vaccine	Streptococcus pneumoniae
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Influenza vaccination with PCV13	Influenza vaccination with PCV13	Korea University Guro Hospital	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Investigational 23-valent PPV	Investigational 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
3. Pfizer · 6 drugs in this class
4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
5. Henogen · 3 drugs in this class
6. Pfizer Inc. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
9. BioNTech · 2 drugs in this class
10. Merck Sharp & Dohme LLC · 2 drugs in this class